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Abstract
Background: Increasing evidence suggests a close relationship between systemic inflammation and cancer
development and progression. The neutrophil to lymphocyte ratio (NLR) has been shown to be an independent
prognostic indicator in various advanced and localized cancers. We investigated the influence of markers of systemic
inflammation such as leucocyte counts and metabolic co-morbidities on overall survival (OS) after radiotherapy for
localized prostate cancer.
Methods: We conducted a retrospective study of patients with localized prostate cancer treated with definitive
external beam radiotherapy or brachytherapy. Univariate and multivariate cox proportional hazards models were
used to investigate the influence of the following factors on OS: age, neutrophil and lymphocyte counts,
neutrophil-to-lymphocyte ratio (NLR), Cancer of the Prostate Risk Assessment (CAPRA) score as well as
comorbidities associated with inflammation such as cardiac history, diabetes and use of a statin. A stepwise
selection of variable based on the Akaike information criterion (AIC) was used for multivariate analysis.
Results: In total, 1772 pts were included; blood count data was available for 950 pts. Median age was 68 years (44–87).
Actuarial 5 years OS and biochemical recurrence-free survival (BRFS) for the 1772 patients were 93 % and 95 %,
respectively, with a median follow-up of 44 months (1–156). On univariate analysis, neutrophil count (p = 0.04), cardiac
history (p = 0.008), age (p = 0.001) and CAPRA (p = 0.0002) were associated with OS. Lymphocytes, NLR and
comorbidities other than cardiac history were not associated with mortality. On multivariate analysis, neutrophil count
(HR = 1.18, 95 % CI: 1.017-1.37, p = 0.028), age (HR = 1.06, 95 % CI: 1.01-1.1, p = 0.008) and CAPRA (HR = 1.16, 95 % CI:
1.03-1.31, p = 0.015) were independent predictors of OS.
Conclusion: Neutrophil count, as a possible marker of systemic inflammation, appear to be an independent prognostic
factor for overall mortality in localized prostate cancer. A validation cohort is needed to corroborate these results.
Background
Inflammation is a fundamental innate immune re-
sponse associated with disruption of homeostasis. In-
creasing evidence suggests a close relationship between
systemic inflammation and cancer development and
progression [1–4]. Inflammatory leukocytes such as
neutrophils, monocytes, macrophages, and eosinophils
provide the soluble factors that are thought to mediate
the development of inflammation-associated cancer. In
recent years, several readily measurable peripheral
blood markers such as the neutrophil to lymphocyte
ratio (NLR) [5–10], the Glasgow Prognostic score (con-
sisting in a combination of C-reactive protein and albu-
min level) [11–13], the platelet to lymphocyte ratio [14,
15] or the Prognostic index (consisting in white blood
cell count and C-reactive protein) [16], were associated
with cancer outcomes in large cohort studies. More
specifically, the NLR has been recognized as an inde-
pendent prognostic indicator in various advanced and
localized cancer including gastro-intestinal cancers [6,
9, 17–21], urological cancers [5, 10, 22, 23], lung can-
cers [8, 24], head and neck cancers [7, 25], ovarian can-
cers [8], and glioblastomas [7]. In the case of prostate
cancer, studies have reported that NLR was associated
with treatment response and survival in patients with
metastatic castrate resistant prostate cancer receiving
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systemic therapy [22, 26]. However, the prognostic
value of markers of systemic inflammation was never
previously evaluated in the context of localized prostate
cancer.
The following study was designed to explore the influ-
ence of readily available markers of systemic inflammation
such as leucocyte count and metabolic co-morbidities
associated with systemic inflammation on biochemical
recurrence-free survival (BRFS) and overall survival (OS)
after curative radiotherapy for localized prostate cancer in
a large cohort of patients.
Methods
Patients’ characteristics
Institutional review board (IRB) approval from the
Centre Hospitalier de l’Université de Montréal (CHUM)
was obtained for this study (Ref 14.144). This being a
retrospective study, informed consent was waived by the
IRB.
A review of our institutional database of patients with
localized prostate cancer treated with definitive external
beam radiotherapy or brachytherapy from September
2001 to June 2014 was conducted. Inclusion criteria were:
(1) Eastern Cooperative Oncology Group performance
status < 2, (2) histology proven prostate cancer; (2) local-
ized prostate cancer stage T1-3bN0M0 as per the
American Joint Committee on Cancer 7th edition; (3)
brachytherapy or external beam radiotherapy(EBRT) or a
combination of both with curative intent. Prostate cancer
risk group was defined as per the National Comprehensive
Cancer Network (NCCN) Guidelines classification [27].
Patients with evidence of radiological or histological
lymph node involvement or distant metastasis were
excluded. Patients receiving androgen deprivation therapy
were included. Initial work-up at diagnosis included:
medical history including presence of co-morbidities,
physical examination including digital rectal examination,
complete blood count and biochemistry, serum prostate
specific antigen (PSA), transrectal ultrasound and biopsy.
For patients with stage T3-4 disease, PSA ≥10 ng/mL or a
Gleason score (GS) ≥7, staging bone scan and pelvic com-
puted tomography (CT) were done at the treating physi-
cian’s discretion to exclude distant metastasis.
Treatment characteristics
All patients were treated with curative radiotherapy, with
or without androgen deprivation therapy. Low dose rate
(LDR) brachytherapy alone with Iodine125 permanent
seeds to a dose of 144 grays (Gy) was considered for
low-risk prostate cancer or intermediate-risk prostate
cancer with favorable features. Combined brachytherapy
and EBRT (LDR dose of 110 Gy and EBRT dose of
44 Gy in 22 fractions versus HDR dose of 15 Gy in 1
fraction and EBRT dose of 37.5 Gy in 15 fractions) was
considered for intermediate or high-risk prostate cancer.
When EBRT was given as exclusive therapy, a dose of 70
to 80 Gy was given with or without hormonal therapy.
Follow-up and statistics
Standard follow-up for all patients typically included:
physical examination and serum PSA every 3 months for
the first 2 years, every 6 months for the following 3 years,
and annually thereafter. Biochemical failure was defined
as per the Phoenix consensus (nadir + 2 ng/mL) [28].
Follow-up duration was defined as the time from the
date of treatment completion to the date of last follow-
up or death. Kaplan-Meier method was used for estima-
tion of OS and BRFS. Univariate and multivariate Cox
proportional hazards models analysis were performed to
determine predictors of OS and BRFS. Potential baseline
predictive factors explored included: age, UCSF Cancer
of the prostate risk assessment score (CAPRA) (combin-
ing age, PSA, Gleason score, clinical stage and percent
positive biopsy cores), body mass index (BMI), metabolic
co-morbidities associated with systemic inflammation
(cardiovascular disease, diabetes, hypertension, use of
statins), as well as leucocyte counts (neutrophils, lym-
phocytes and neutrophil-to-lymphocyte ratio). Multivari-
ate analysis was carried using stepwise regression
method. A stepwise selection of variable based on the
Akaike information criterion (AIC) was used for multi-
variate analysis to determine the best fit model [29].
Statistical analyses were conducted using SPSS 17 (SPSS,
Chicago, IL), SAS 9.4 (SAS Institute, Cary, NC) and R
version 2.15.2. All reported p values were considered to
be statistically significant at <0.05 from two-sided tests.
Results
Patients’ characteristics
In total, 1772 patients were included in the analysis;
blood count data was available for 950 patients. Median
age was 68 years (range: 44–87). The majority of patients
(64 %) presented with stage T1 disease. Low, intermedi-
ate and high risk prostate cancer constituted respectively
41 %, 49 % and 10 % of the cohort. In total, 42 % of pa-
tients presented a CAPRA score of 0–2, 46 % of 3–5
and 12 % of 6–10. Patients’ characteristics including
metabolic co-morbidities and leucocyte counts as well as
treatment characteristics are summarized in Table 1. Co-
morbidities included diabetes in 15.1 % of patients, car-
diovascular disease in 34.6 % and hypertension in
45.7 %. In addition, 42.6 % of patients used a statin for
hypercholesterolemia.
Biochemical and overall survival outcomes and predictive
factors
Actuarial 5 years OS and BRFS for the entire cohort (1772
patients) was respectively 93 % and 95 %, with a median
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follow-up of 44 months (range: 1–156) (Figs. 1 and 2). On
univariate analysis, neutrophil count (p = 0.04), cardiac his-
tory (p = 0.009), age (p = 0.001) and CAPRA (p = 0.0002)
were associated with OS (Table 3). Lymphocytes, NLR and
comorbidities other than cardiac history were not associ-
ated with mortality. On multivariate analysis, neutrophil
count (HR = 1.18, 95 % CI: 1.017-1.37, p = 0.028), age
(HR = 1.06, 95 % CI: 1.01-1.1, p = 0.008) and CAPRA
(HR = 1.16, 95 % CI: 1.03-1.31, p = 0.015) were inde-
pendent predictors of OS (Table 2).
On univariate analysis, only CAPRA was associated
with BRFS (p = 0.0001). On multivariate analysis, both
age (HR = 0.94, 95 % CI 0.91-0.98, p = 0.009) and
CAPRA (HR = 1.26, 95 % CI 1.12-1.43, p = 0.0002) were
associated with BRFS (Table 3).
Discussion
To our knowledge, this is the first study in the literature
reporting an association between neutrophil count and
prognosis in localized prostate cancer. In our large study
cohort, neutrophil counts were found to be associated
with worse OS outcomes. However, such an association
was not found for BRFS nor was it found for other
markers such as NLR. In addition, in concordance with
previous literature [30, 31], chronological age as well as
CAPRA- score as indicator of cancer aggressiveness,
were expectedly associated with OS.
The association of neutrophils with survival found in this
study is in agreement with the now established association
between systemic inflammation and cancer outcomes in
many different cancers [1, 32–34], and the increasing evi-
dence supporting the prognostic importance of neutrophil
count as a marker of inflammation [23, 35, 36]. The
prognostic significance of neutrophil counts was recently
suggested in metastatic prostate cancer. In fact, in a first
study by Keizman [26] where the association between
pretreatment NLR and cancer outcome in 156 patients
with metastatic castration-resistant prostate cancer treated
with ketoconazole was assessed, pretreatment NLR >3 was
Table 1 Patients and treatments characteristics
Age (y)
Median (range) 67 44-87
PSA at diagnosis (ng/mL)
Median (range) 8.1 0.2-132
AJCC tumor classification (N, %)
T1 1126 64 %
T2 627 32 %
T3 80 4 %
Gleason score (N; %)
≤6 930 53 %
7 752 42 %
≥8 90 5 %
NCCN risk groups (N; %)
Low 748 42 %
Intermediate 855 48 %
High 169 10 %
PPC (N, %)
<34 % 883 50 %
≥34 % 883 50 %
CAPRA score>
0-2 759 43 %
3-5 811 46 %
6-10 194 11 %
BMI
Median (range) 28.2 13.9–52.5
Diabetes (N; %)>
Yes 272 15 %
No 1500 85 %
Statin use (N; %)>
Yes 762 43 %
No 1010 57 %
CVD (N; %)
Yes 629 35 %
No 1143 65 %
HTN (N; %)
Yes 815 46 %
No 957 54 %
Lymphocytes (103 cells/μL)
Median (range) 1.7 0.4–16
Neutrophils (103 cells/μL)
Median (range) 4.5 0.9–12
NLR
Median (range) 3.0 0.1–18.4
Treatment characteristics
Radiotherapy
Table 1 Patients and treatments characteristics (Continued)
HDR brachytherapy 52 3 %
LDR brachytherapy 901 51 %
EBRT 815 46 %
Androgen deprivation>
Non 1551 87 %
Yes 221 13 %
PSA = prostate-specific antigen; AJCC = American Joint Committee on Cancer;
NCCN= National Comprehensive Cancer Network; PPC = percentage of positive
cores at prostate biopsies; CAPRA = Cancer of the Prostate Risk Assessment score,
BMI = body mass index; CVD = cardiovascular disease; HTN = hypertension.
>HDR= High dose rate; LDR = Low dose rate. Lymphocytes, neutrophils and NLR
were available for 950 patients; BMI was available for 544 patients; data was
available for entire cohort (1772 patients) for all the other factors.
Bahig et al. BMC Cancer  (2015) 15:594 Page 3 of 8
found to be associated with worse progression-free survival
(PFS) but was not associated with OS. In a second retro-
spective study including 33 patients with metastatic
castrate resistant prostate cancer treated with docetaxel
and prednisone [37], an increased NLR was found to be
associated with a decreased PSA response.
Inflammation in cancer and neutrophil count
How neutrophils affect cancer prognosis remain unclear.
Systemic inflammation is believed to be associated with
cancer progression through several mechanisms, includ-
ing: cancer cell development, proliferation and survival,
angiogenesis, metastatic potential increase and diminished
response to therapy [2]. In metastatic prostate cancer,
molecular signaling triggered by inflammatory mediators
was hypothesized to promote cancer cell progression [38].
Neutrophils are hypothesized to contribute to tumor
progression and aggressive biology through the produc-
tion of cytokines (such as such as tumor necrosis factor,
interleukin (IL)-1, and IL-6), chemokines and granule
Fig. 1 Kaplan Meier OS curve with lower and upper limits of the 95 % confidence intervals showing a 5-year OS of 93 % (95 % CI = 91–95 %) in
patients with localized prostate cancer treated with radical radiotherapy or brachytherapy
Fig. 2 Kaplan Meier BRFS curve with lower and upper limits of the 95 % confidence intervals showing a 5-year BFRS of 95 % (95 % CI = 93–96 %)
in patients with localized prostate cancer treated with radical radiotherapy
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proteins, which are thought to promote tumor prolifera-
tion and angiogenesis, and increase its metastatic potential
[18, 39, 40]. On the other hand, the adverse prognosis
associated with high NLR could also partly be explained
by a lower lymphocyte count which can reflect a de-
creased anti-tumor immune response, an increased neu-
trophil response to the tumor and which consequently
favors angiogenesis and tumor progression or both [41].
This being a retrospective study, we were unable to in-
clude other known factors of inflammation such as C-
reactive protein or albumin levels in this study, because
they are not routinely included in laboratory investigations
of localized prostate cancer. Neutrophil count and NLR
have the advantage of being inexpensive and readily avail-
able markers of systemic inflammation. However, although
numerous studies support their prognostic role, cut-off
values vary significantly among studies, complicating its
current use in the clinical setting.
Neutrophil count as prognostic indicator in cancer
Several studies have reported an association between
increased peripheral neutrophil count and prognosis in
numerous cancers, predominantly locally advanced or
metastatic. In a study by Teramukai [36], increased
neutrophil count was associated with both decreased OS
and PFS in patients with stage IIIB and IV non-small cell
lung cancer. Similarly, EORTC 18951 trial showed that
both pre-treatment neutrophil and leukocyte counts
were independent prognostic factor for OS in patients
with metastatic melanoma undergoing immunotherapy
[35]. In addition, a high baseline NLR was found to be a
predictor of poor prognosis in many cancers treated with
Table 2 Univariate and multivariate analysis of factors associated with OS
Univariate Multivariate
HR (95 % CI) p-value HR (95 % CI) p-value
Age (n = 1772) 1.06 (1.03 1.10) 0.001 1.05 (1.01–1.10) 0.008
CAPRA (n = 1772) 1.21 (1.09–1.34) 0.0002 1.16 (1.03–1.30) 0.015
BMI (n = 544) 1.00 (0.93–1.06) 0.9
CVD (n = 1772) 1.79 (1.16–2.77) 0.009
HTN (n = 1772) 1.14 (0.74–1.76) 0.5
Diabetes (n = 1772) 1.59 (0.94–2.68) 0.08
Statin use (n = 1772) 0.82 (0.52–1.28) 0.4 0.70 (0.42–1.14) 0.15
Neutrophils (n = 950) 1.16 (1.01–1.34) 0.04 1.18 (1.017–1.37) 0.03
Lymphocytes (n = 950) 1.01 (0.72–1.43) 0.9
NLR (n = 950) 1.10 (0.95–1.27) 0.2
WBC (n = 950) 1.13 (0.99–1.28) 0.06
n = number of patients with available data
WBC = white blood count (=Neutrophils + Lymphocytes)
Table 3 Univariate and multivariate analysis of factors associated with BRFS
Univariate Multivariate
HR (95 % CI) p-value HR (95 % CI) p-value
Age (n = 1041) 0.98 (0.94–1.01) 0.2 0.94 (0.91–0.98) 0.009
CAPRA (n = 1041) 1.23 (1.11–1.37) 0.0001 1.26 (1.12–1.43) 0.0002
BMI (n = 372) 1.02 (0.97–1.08) 0.5
CVD (n = 1044) 0.73 (0.46–1.16) 0.2
Diabetes (n = 1044) 0.86 (0.44–1.67) 0.7
Statin use (n = 1044) 0.79 (0.50–1.24) 0.3 0.67 (0.39–1.17) 0.2
Neutrophils (n = 608) 1.04 (0.87–1.23) 0.7
Lymphocytes (n = 609) 0.98 (0.64–1.48) 0.9
NLR (n = 608) 1.02 (0.85-1.22) 0.9
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systematic therapy including: malignant mesothelioma
[42], colorectal cancer metastatic to liver [17], pancreatic
cancer [6], gastric cancer [20] or advanced esophageal
cancer [21].
One could assume that increased peripheral neutrophils
would be associated with worse outcomes in systemic dis-
ease only, but numerous studies have reported similar
results in localized cancers. In fact, in patients undergoing
radical surgery for limited stage cancers, high pre-opera-
tive NLR was associated with both worse OS and DSS in
colorectal cancer [43], hepatocellular carcinoma [9],
bladder cancer [10] renal carcinoma [5], gastric cancer
[44], and early stage non-small cell lung cancer [24]. In
addition, increased baseline NLR was associated with
poorer OS in patients undergoing treatment for glioblast-
oma multiforme [7] and nasopharygeal cancer [25]. In our
study, neutrophils were predictive of OS but no such asso-
ciation was found with BRFS. In addition, NLR was associ-
ated with neither OS nor BRFS. It is therefore difficult to
determine whether systemic inflammation was the cause
for cancer progression or simply a marker for systemic in-
flammation, which could be a cause for an increase in
mortality. The number of deaths was too small to stratify
according to cause of death in order to determine whether
patients with high neutrophils were more likely to die
from cardiac problems or prostate cancer. This will be the
subject of a later analysis after longer follow-up.
Other markers of systemic inflammation
Many studies have looked at other markers of systemic
inflammation. In fact, C-reactive protein alone [32], the
Glasgow prognostic score constituting a combination of
C-reactive protein and albumin levels [12], the platelet
to lymphocyte ratio [14, 15] or the Prognostic index
constituted of a combination of C-reactive protein and
white cell count [11], were all shown to be associated
with survival in cancer patients. Independent of tumor
stage, the Glasgow prognostic score has comprehensively
been validated to be prognostic in lung, gastro-intestinal
and renal cancers [3]. In a large cohort of 27 031 cancer
patients, Proctor at al. [13] reported that both the Glas-
gow score and the Prognostic index had similar prog-
nostic value in cancer, independent of cancer type.
Interestingly, their results suggested that rather than the
NLR, leucocytes may be best useful addition to the
Glasgow score.
Limitations of our study include its retrospective
nature with associated selection bias, possible confound-
ing factors and missing data. As leukocyte data was not
available for all patients, our study may have been
underpowered to detect a statistically significant differ-
ence in NLR or lymphocyte counts. Additional known
inflammatory markers such as C-reactive protein and
albumin level were not routinely available and therefore
could not be included in the analysis. In addition, the
small number of events and lack of validation cohort
precluded the decision to determine a clinically useful
neutrophil and age cut-off based on this cohort.
However, we believe that results from this large cohort
of patients should be considered at time of treatment
decision, especially in older patients. Readily available
inflammatory marker such as neutrophil count o better
predict survival outcomes and therefore guide optimal
treatment decision-making. In fact, a significant propor-
tion of localized prostate cancer is diagnosed in an older
population of patients aged ≥ 70 years. For these patients,
treatment aggressiveness can vary widely, from watchful
waiting to radical local treatment associated with systemic
androgen deprivation therapy, depending on their predicted
survival outcomes. In addition, a better understanding of
the mechanism by which these inflammatory markers con-
tribute to poorer survival may open the door to new targets
of systemic therapies.
Conclusion
Overall mortality in localized prostate cancer depends
not only on age and cancer aggressiveness, but also on
neutrophil count as a marker of systemic inflammation.
Neutrophil counts may prove useful in treatment deci-
sion algorithm of these patients. A validation cohort is
needed to corroborate these results.
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